Read by QxMD icon Read

Lymphoma FDG PET/CT

Entao Liu, Siyun Wang, Peilong Lai, Zhouyang Lian, Shuxia Wang
A 36-year-old woman with a 2-week history of fever and markedly elevated lactate dehydrogenase levels. Nonenhanced CT and contrast-enhanced CT showed hepatosplenomegaly, diffusely decreased attenuation of the liver, and homogeneous enhancement in the hepatic and splenic parenchyma. 18F-FDG PET/CT revealed diffuse intense heterogeneous uptake by the liver (like superscan in bone scintigraphy). A liver needle biopsy confirmed the diagnosis of hepatosplenic alphabeta T-cell lymphoma. Subsequently, she received chemotherapy...
May 14, 2018: Clinical Nuclear Medicine
Vanessa Sanders, Joseph Donald, Barry A Siegel
An 89-year-old woman presented with seizure and hyponatremia. CT and MRI demonstrated mass-like enlargement of the adrenal glands and multiple pulmonary nodules. PET/CT performed to evaluate for metastatic disease demonstrated intense 18F-FDG uptake within enlarged adrenal glands. Given mild uptake in the pulmonary nodules, the differential diagnosis for the adrenal uptake included lymphoma, granulomatous infection, and less likely, metastatic lung cancer.
May 14, 2018: Clinical Nuclear Medicine
Michael W Cho, Bennett B Chin
Hepatosplenic Gamma Delta T cell lymphoma (γδHSTL) is a rare, highly aggressive, and rapidly lethal T cell lymphoma which manifests 18 F-FDG PET/CT findings that can mimic benign conditions. Patients with γδHSTL present with unexplained symptoms of a hematologic malignancy like the B symptoms of lymphoma including weight loss, fevers, and night sweats, as well as, splenomegaly and hepatomegaly. Thrombocytopenia, anemia, or neutropenia are also common due to spleen, liver and bone marrow involvement. The peripheral blood, however, typically does not show abnormal T cells...
2018: American Journal of Nuclear Medicine and Molecular Imaging
Aatif Parvez, Noam Tau, Douglas Hussey, Manjula Maganti, Ur Metser
PURPOSE: To determine whether metabolic tumor parameters and radiomic features extracted from 18 F-FDG PET/CT (PET) can predict response to therapy and outcome in patients with aggressive B-cell lymphoma. METHODS: This institutional ethics board-approved retrospective study included 82 patients undergoing PET for aggressive B-cell lymphoma staging. Whole-body metabolic tumor volume (MTV) using various thresholds and tumor radiomic features were assessed on representative tumor sites...
May 12, 2018: Annals of Nuclear Medicine
Casey E Bohl, Sara M Federico, Giles W Robinson, Armita Bahrami, Barry L Shulkin
PURPOSE: Primary pancreatic carcinoma and pancreatic metastases are rare in the pediatric population. Pancreatoblastoma is the most common pancreatic malignant tumor in young children and solid-pseudopapillary tumor in teenagers. Pancreatic adenocarcinoma is extremely rare under the age of 40 and is usually associated with underlying genetic abnormalities. Secondary malignancies of the pancreas occur more frequently than primary pancreatic malignancies in children and are most commonly seen with non-Hodgkin lymphomas (NHL) and mesenchymal sarcomas...
May 11, 2018: Pediatric Blood & Cancer
Soo Bin Park, Jung Mi Park, Seung Hwan Moon, Young Seok Cho, Jong-Mu Sun, Byung-Tae Kim, Kyung-Han Lee
BACKGROUND: When subjects without a known malignancy present with suspicious skeletal lesions, differential diagnosis and primary cancer identification is important. Here, we investigated the role of FDG PET/CT in this clinical situation. METHODS: We enrolled 103 patients with no known malignancies who were referred for FDG PET/CT because of bone lesions that were suspicious for cancer metastasis. Each extra-skeletal FDG lesion was categorized as consistent with primary cancer or with metastasis based on the distribution and pattern of all abnormal lesions in the individual...
2018: PloS One
Rômulo Hermeto Bueno do Vale, Daniela Andrade Ferraro, Paulo Schiavom Duarte, Giovana Carvalho, Marcos Santos Lima, George Barbério Coura Filho, Marcelo Tatit Sapienza, Carlos Alberto Buchpiguel
Objective: To compare the degree of benign bone marrow uptake of 18 F-fluorodeoxyglucose (18 F-FDG) between Hodgkin lymphoma patients with and without B symptoms. Materials and Methods: We analyzed the medical charts of 74 Hodgkin lymphoma patients who underwent 18 F-FDG positron emission tomography/computed tomography (PET/CT) prior to the initiation of therapy between October 2010 and September 2013. In all of the patients, the bone marrow biopsy was negative and the 18 F-FDG PET/CT images did not suggest bone marrow involvement...
March 2018: Radiologia Brasileira
Angelina Cistaro, Laura Cassalia, Cinzia Ferrara, Natale Quartuccio, Laura Evangelista, Maurizio Bianchi, Franca Fagioli, Gianni Bisi, Sergio Baldari, Alessandro Zanella, Marta Pillon, Pietro Zucchetta, Marta Burei, Alessandra Sala, Luca Guerra, Priscilla Guglielmo, Roberta Burnelli, Stefano Panareo, Federica Scalorbi, Ilaria Rambaldi, Arnoldo Piccardo, Alberto Garaventa, Demetrio Familiari, Maria Concetta Fornito, Egesta Lopci, Maurizio Mascarin, Corinna Altini, Cristina Ferrari, Teresa Perillo, Nicola Santoro, Eugenio Borsatti, Giuseppe Rubini
INTRODUCTION: The present study investigated the utility of fluorine-18 (18 F) fluoro-2-deoxy-d-glucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). PATIENTS AND METHODS: A total of 224 pediatric patients with HL underwent 18 F-FDG PET/CT at staging. BMB or follow-up imaging was used as the standard of reference for the evaluation of BMI...
April 14, 2018: Clinical Lymphoma, Myeloma & Leukemia
Coreline N Burggraaff, Alexander C Cornelisse, Otto S Hoekstra, Pieternella J Lugtenburg, Bart de Keizer, Anne I J Arens, Filiz Celik, Julia E Huijbregts, Henrica C W De Vet, Josee M Zijlstra
We aimed to assess the interobserver agreement of Interim PET (I-PET) and End-of-Treatment PET (EoT-PET) using the Deauville 5-point scale (DS) in first-line DLBCL patients. Methods: I-PET and EoT-PET scans of DLBCL patients were performed in the HOVON84 study (2007-2012), an international multicenter randomized controlled trial. Patients received R-CHOP14 and were randomized to receive rituximab intensification in the first 4 cycles or not. I-PET was made after 4 cycles (for observational purposes), and EoT-PET scan after 6 or 8 cycles...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Pierre Decazes, Stéphanie Becker, Mathieu Nessim Toledano, Pierre Vera, Paul Desbordes, Fabrice Jardin, Hervé Tilly, Isabelle Gardin
INTRODUCTION: Our aim was to study the prognostic value of two new 18 F-FDG PET biomarkers in diffuse large B-cell lymphoma (DLBCL). We examined the total tumor surface (TTS), describing the tumor-host interface, and the tumor volume surface ratio (TVSR), corresponding to the ratio between the total metabolic tumor volume (TMTV) and TTS, describing the tumor fragmentation. METHODS: We retrospectively included 215 patients with DLBCL. Patients underwent initial 18 F-FDG PET/CT before R-CHOP (73%) or intensified R-CHOP (R-ACVBP) regimens (27%)...
April 28, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Nieves Gómez León, Gema Vega, Beatriz Rodríguez-Vigil Junco, Carlos Suevos Ballesteros
BACKGROUND AND OBJECTIVES: To prospectively compare the accuracy in initial staging and end-of-treatment restaging of diffuse large B-cell lymphoma (DLBCL) between 64-slice multidetector computed tomography (64MDCT) and 18FDG positron emission tomography/computed tomography (18FGD PET/CT) with intravenous contrast injection. MATERIAL AND METHODS: Randomised and blind controlled clinical multicentric trial that included biopsy-proven DLBCL patients. Seventy-two patients from five different hospitals in the region of Madrid, Spain, were enrolled in the study between January 2012 and June 2015...
April 25, 2018: Medicina Clínica
Hayahiko Fujii, Hiroaki Tanaka, Yohei Nomoto, Naoki Harata, Sayako Oota, Jun Isogai, Katsuya Yoshida
The purpose of this study was to investigate the efficacy of F-fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for evaluating the ocular adnexal lymphoma treatment responses.We retrospectively reviewed data for 9 histologically confirmed cases of malignant lymphoma. All patients had at least one ocular adnexal tumor site and underwent FDG PET/CT before and after treatment. Patients' histological disease subtypes included diffuse large B-cell lymphoma (n = 3), mucosa-associated lymphoid tissue lymphoma (n = 2), follicular lymphoma (n = 1), NK/T-cell lymphoma (n = 1), lymphoplasmacytic lymphoma (n = 1), and Hodgkin lymphoma (n = 1)...
April 2018: Medicine (Baltimore)
Jing Zhou, Yigang Zhao, Zhengxing Gou
RATIONALE: Bilateral adrenal diffuse large B-cell lymphoma, nongerminal center B-cell phenotype (non-GCB DLBCL), is an uncommon malignancy that exhibits rapid development. Fluorine-18-fluorodeoxyglucose position emission tomography/computed tomography (CT) is extremely sensitive in distinguishing highly malignant tumors from benign tumors. PATIENT CONCERNS: We report a case of non-GCB DLBCL showing significantly high uptake of 18F-FDG on PET/CT examination. DIAGNOSES: Histopathological and immunohistochemical examination further confirmed that the bilateral adrenal masses were non-GCB DLBCL...
April 2018: Medicine (Baltimore)
Barbara Salvatore, Rosa Fonti, Amalia De Renzo, Sara Pellegrino, Ida L Ferrara, Ciro G Mainolfi, Luana Marano, Carmine Selleri, Fabrizio Pane, Silvana Del Vecchio, Leonardo Pace
BACKGROUND: We evaluated the role of [18F]FDG PET/CT in tumor response assessment and prognosis of Primary Extranodal Lymphoma (PEL) patients. METHODS: We examined retrospectively, 56 PEL patients: 31 with aggressive diffuse large B cell lymphoma (DLBCL) and 25 with indolent lymphoma (20 mucosa-associated lymphoid tissue lymphoma-MALT and 5 follicular lymphoma). All patients had undergone [18F]FDG PET/CT at diagnosis (PET-I) and 50 of them also after therapy (PET-II)...
April 24, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
Jianhua Zhang, Yan Fan, Meng Liu, Qian Li, Rongfu Wang
An 81-year-old woman presented a 2-month history of left upper gum swelling. Biopsy of the lesion revealed the diffuse large B-cell lymphoma. F-FDG PET/CT scan showed the abnormal high uptake at the left upper gum.
April 23, 2018: Clinical Nuclear Medicine
Shelvin Kumar Vadi, Rajender Kumar, Bhagwant Rai Mittal, Harmandeep Singh, Amanjit Bal, Gaurav Prakash, Anish Bhattacharya
Neoplasms arising from the urachus are extremely rare. We present a case of a young woman with mild abdominal pain and a palpable swelling in the mid abdomen with incidental detection of a subumbilical mass. Repeated fine-needle aspiration cytology failed to reveal the true nature of the lesion. F-FDG PET/CT showed tracer uptake in the cranial end of urachal remnant lesion. Core biopsy from the site with maximal FDG uptake turned out to be lymphomatous involvement in urachus, which is extremely rare and previously unreported...
April 23, 2018: Clinical Nuclear Medicine
Yassine Al Tabaa, Emmanuelle Tchernonog, Pierre Faurie, Anne Ségolène Cottereau, Hélène Monjanel, Antoine Bonnet, Steven Le Gouill, Emmanuel Gyan, Hervé Ghesquieres, Denis Mariano-Goulart, Guillaume Cartron
PURPOSE: Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B cell lymphomas (DLBCL) clinically characterized by a poorer prognostic. Few clinical and imaging data are available and derived from pooled case reports and small series. The aim of the study was to evaluate the FDG avidity at baseline and the utility of 18-Fluorodeoxyglucose (FDG) positron-emission-tomography/computed-tomography (PET/CT) for staging and response assessment. METHODS: Patients with newly diagnosed PBL seen at Lymphoma Study Association centers during the period 2005-2015 were included if they underwent a PET/CT at staging and at the end of treatment (eotPET) and had received an anthracycline-based first line therapy...
April 20, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Yumei Chen, Mingge Zhou, Jianjun Liu, Gang Huang
Purpose: The value of 18 F-fluorodeoxyglucose positron emission tomography /computed tomography (18 F-FDG PET/CT) in assessing bone marrow involvement (BMI) of lymphoma remains controversial. The present study aims to evaluate the prognostic meaning of bone marrow FDG uptake pattern in PET/CT of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. Materials and Methods: 193 newly diagnosed DLBCL patients were retrospectively analyzed. All patients received 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...
2018: Journal of Cancer
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin's lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin's lymphoma and PMBCL...
April 18, 2018: Nuclear Medicine Communications
Hanna Bernstine, Liran Domachevsky, Meital Nidam, Natalia Goldberg, Ifat Abadi-Korek, Ofer Shpilberg, David Groshar
To compare positron emission tomography (PET) standardized uptake value (SUV) with magnetic resonance (MR) apparent diffusion coefficient (ADC) of nodal target lesions in patients with F-fluoro-2-deoxyglucose (FDG)-avid lymphomas by simultaneous PET/MR.Patients with histologically proven Hodgkin and non-Hodgkin lymphoma underwent PET/MR limited field of view of FDG-avid target nodal lesions. For PET images, a region of interest (ROI) was drawn around the target nodal lesion and the SUVmax and SUVmean was measured...
April 2018: Medicine (Baltimore)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"